Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company focused on developing innovative treatments for Attention Deficit Hyperactivity Disorder (ADHD), announced its financial results for the year ended December 31, 2025, alongside significant operational updates. The company reported a net loss of $22.4 million for the year, an increase from $16.6 million in 2024, primarily due to rising general and administrative expenses and interest on notes payable. Despite the losses, Cingulate highlighted key achievements, including the issuance of a Notice of Allowance for a patent application covering its lead asset, CTx-1301, which is designed to provide a new treatment option for ADHD. This patent, once granted, will extend protection through May 2042, further solidifying Cingulate's intellectual property portfolio. Additionally, the company successfully closed a $12 million private investment in public equity (PIPE) financing, which is expected to support its ongoing regulatory efforts and commercialization preparations for CTx-1301. Cingulate's CEO, Shane J. Schaffer, emphasized the company's commitment to advancing its Precision Timed Release (PTR) platform, which aims to improve medication delivery for ADHD patients. The FDA has accepted the New Drug Application (NDA) for CTx-1301, with a target action date set for May 31, 2026. Cingulate is actively preparing for commercial launch, pending regulatory approval, and is focused on scaling manufacturing and enhancing market access strategies. The company remains optimistic about its future prospects, aiming to create long-term value for both patients and shareholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.